BioGenex designs, develops and commercializes molecular pathology systems for Tumor diagnosis, prognosis, precision medicine and life science research. BioGenex’s industry-leading next-generation cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are revolutionizing pathology. Proprietary fully-automated molecular pathology workstations from BioGenex are the most advanced systems available globally. BioGenex prides itself on delivering cutting edge technology, years ahead of the competition, providing the finest systems for immunohistochemistry (IHC), in situ hybridization (ISH), Fluorescence ISH (FISH) and in situ PCR. BioGenex systems and product performance are guaranteed: antibodies, probes, antigen retrieval, detection systems, and histology stains. We provide quality systems and are committed to best in class customer care.
Facts and Figures:
Mission: To Enable Pathologists and Clinicians for Precise Diagnosis and Improved life of Cancer Patient
Founders: Krishan L. Kalra, Ph.D., Satya Kalra
CEO: Krishan L. Kalra, Ph.D.
Incorporation: San Ramon, California, 1981
Industry: Tissue and cell-based Tumor diagnostics
Locations:
Headquarters: Fremont, California, USA
Regional Center of Excellence: Hyderabad, India
Manufacturing Sites: Fremont, California, USA and Hyderabad, India
Agency Office: Shanghai, China
Customer Service Centers: Fremont, Hyderabad and Shanghai
Regulatory Certifications: ISO 13485 (2016), ISO 9001 (2015), cGMP, IVD – CE certified
Number of Employees: 250+ globally
Product Areas:
- Multiple fully automated molecular pathology workstations
- Immunohistochemistry (IHC)
- In-situ hybridization (ISH)
- Fluorescence in-situ hybridization (FISH)
- Multiplex stains
- MicroRNA and HPV probe system
Flagship Products: Xmatrx® systems, i6000™ systems, i500 Plus™, NanoVIP®, Xmatrx® MINI, EZ-Retriever®, IHC primary antibodies, microRNA probes, IHC/ISH Detection kits
Global Reach: 70+ distributors across 47 countries
Customers: Pathologists, histotechnologists, reference labs, clinical lab professionals, pharmaceutical/biotechnology and academic researchers
Patents: 25 US and foreign patents granted, 28 US and foreign patents pending